U.S. drug inspectors uncovered serious quality control problems at an Eli Lilly pharmaceutical plant that is ramping up to manufacture one of two promising COVID-19 drugs touted by President Trump as "a cure" for the disease, according to government documents and three sources familiar with the matter.
Jillian Kitchener reports